Vapreotide Acetate/ RC 160 CAS 103222-11-3 Treatment For acute esophageal variceal bleeding

Vapreotide Acetate/ RC 160 CAS 103222-11-3 Treatment For acute esophageal variceal bleeding

Product Name: VAPREOTIDE
Synonyms: D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2 (Disulfide bridge Cys2-Cys7);H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2;D-Phe-Cys-Trp-D-Trp-Lys-Val-Cys-Trp-CONH2(disulfide Cys2-Cys7);Vapreotide, RC-160;RC-160;VAPREOTIDE;D-PHE-CYS-TYR-D-TRP-LYS-VAL-CYS-TRP-NH2;FCYWKVCW-NH2
CAS: 103222-11-3
MF: C57H70N12O9S2
MW: 1131.37
EINECS:
Product Categories: Somatostatin receptor
Mol File: 103222-11-3.mol

H3Pharma has acquired the worldwide research development and commercial license for vaptan from Debiopharm in Switzerland. 2001 New England Journal of Medicine reported the immediate-release formulation, which was clinically tested and proven by Chemicalbook for early use in the treatment of acute esophageal In 2004, Debiopharm’s subsidiary, the Canadian cancer and endocrinology specialist H3Pharma, developed and manufactured a new drug.

Vapreotide Acetate/ RC 160 CAS 103222-11-3 Chemical Properties
Boiling point 1540.9±65.0 °C(Predicted)
density 1.40±0.1 g/cm3(Predicted)
storage temp. −20°C
pka 9.90±0.15(Predicted)

Function and Application of Vapreotide Acetate/ RC 160 CAS 103222-11-3
1.The immediate release formulation of Sanvar, a somatostatin analogue, is used in the treatment of acute esophageal variceal bleeding (EVB).
2.Sanvar is used prior to endoscopic intervention to control haemorrhage and prevent re-bleeding during the critical five days following the onset of bleeding. EVB is a life threatening condition and the mortality rate is high (about 15% to 25%) in the first six weeks following the haemorrhage. EVB is the cause of about 70% of gastro-intestinal bleeding in patients suffering from liver cirrhosis.
3.Sanvar (vapreotide acetate) is a synthetic octapeptide analogue of the naturally-occurring somatostatin hormone. It has similar pharmacological properties to native somatostatin, but exhibits a longer duration of action. It is the only somatostatin analogue to have demonstrated statistically significant benefits in the early treatment of EVB in association with endoscopic therapy, in a placebo-controlled clinical study (Calès et al. New England Journal of Medicine, 2001). Control of bleeding with survival at five days was achieved more often with Sanvar (p=0.021) than with placebo. Additional